Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Februar 2025

Genmab — Februar 2025

Planlagt Fastgjort Låst Flyttet Genmab
699 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • StockBullS Offline
    StockBullS Offline
    StockBull
    wrote on sidst redigeret af
    #311

    10-15% op

    1 Reply Last reply
    0
    • J Offline
      J Offline
      JKY_VH
      wrote on sidst redigeret af
      #312

      Ja, hvis ikke JNJ´s manglende udmelding om opt in skyggede for kursen

      1 Reply Last reply
      0
      • T Offline
        T Offline
        transalp
        wrote on sidst redigeret af
        #313

        Go morgen.. 🙂

        1 Reply Last reply
        0
        • StockBullS Offline
          StockBullS Offline
          StockBull
          wrote on sidst redigeret af
          #314

          Ja jeg har 235 usd ved PE 13.8. 2025 guiding er jo i usd

          1 Reply Last reply
          0
          • J Offline
            J Offline
            JKY_VH
            wrote on sidst redigeret af
            #315

            Novod løfter kursmålet til 2178, men fortsat hold "Genmab reported solid Q4 revenue of DKK 6,441m, up 38% y/y and 1% ahead of company-compiled consensus and our estimate. Q4 EBIT came in at DKK 2,160m, up 29% y/y and 7% ahead of consensus. For 2025, the company guides for revenue of DKK 24.05-26.35bn (midpoint: DKK 25.2bn) and EBIT of DKK 6.44-9.83bn (midpoint: DKK 8.14bn). Thus, we raise our 2025 top-line estimate by 2% and our EBIT estimate by 18%. We expect consensus estimate revisions of

            1 Reply Last reply
            0
            • J Offline
              J Offline
              JKY_VH
              wrote on sidst redigeret af
              #316

              ~1-2% on the top line as well and 10-15% on EBIT. We finally see estimate revisions going in the right direction, but we stay on the sidelines, as we are still awaiting a high-risk decision from JnJ on Hexabody-CD38, which is still expected in Q1 2025. We maintain our Hold rating, with a higher DCF-derived fair value of DKK 2,178 (2,056)."

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #317

                the announcement of a new Phase 3 trial in 2L+ endometrial cancer by end of year is very promising -in addition to the believe that it will also work in non-small cell lung cancer with patients who have EGFR mutations (with patients currently
                enrolling in that cohort)

                1 Reply Last reply
                0
                • J Offline
                  J Offline
                  JKY_VH
                  wrote on sidst redigeret af
                  #318

                  Så 122 kr. fra Novod er bedre end set længe fra den kant 🙂

                  1 Reply Last reply
                  0
                  • exitnuE Offline
                    exitnuE Offline
                    exitnu
                    wrote on sidst redigeret af
                    #319

                    God morgen 🙂

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #320

                      Jan mentioning that Epkinly is the most advanced candidate for I&I 'and we are in discussions' with AbbVie' on that is another signal this may go forward, think we have to raise the chance that this will happen

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #321

                        Jan on GEN1042 -I can tell you that not only we, but also Biontech is very excited about what we have seen up to now with 1042 -- great potential for combining 1042 with different ADCs -- we'll need a bit more data to get a better feeling for durability, but a high level of excitement.

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #322

                          so even though we still have to be patient for a while, to me it does still sounds
                          very positive for now

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #323

                            Ahmadi confirmed lahn 's scoop that Epcoritamab got the NCCN
                            Category 2A designation with GemOX

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #324

                              So: Effective January 1, 2025, Genmab and Pfizer agreed to amend
                              the License and Collaboration Agreement and
                              the Joint Commercialization Agreement for
                              Tivdak, assigning Genmab sole responsibility
                              for the development and commercialization of
                              Tivdak for second line plus recurrent or metastatic
                              cervical cancer in Europe and all other
                              regions globally, excluding the United States and the China region.

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #325

                                -this means they will need to build european sales force, which they will need anyway for a similar population for Rina-S but also for Acasunlimab

                                1 Reply Last reply
                                0
                                • B Offline
                                  B Offline
                                  bibob
                                  wrote on sidst redigeret af
                                  #326

                                  God morgen. 🙂

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #327

                                    @EL
                                    Or they join with others

                                    1 Reply Last reply
                                    0
                                    • J Offline
                                      J Offline
                                      JKY_VH
                                      wrote on sidst redigeret af
                                      #328

                                      Jyske om dagens aktie Genmab "Vi vurderer, at på aktiens nuværende kursniveau får investorer hele pipelinen samt nogle af de allerede lancerede produkter gratis." https://www.jyskebank.dk/finansnyt/morgennyt/7b36b205-0095-4232-9f06-b95718b64493/!ut/p/z1/rVRdc6IwFP0t--BjJgFikL4hdq3id3UleXGApjQtCRYR6_76DTI7S53t2p3KS3Jv7j3nzJ17gAwGkKmwFElYiEyFqY4pI5uZ2cNG5x5N-rOuhebLkf990VsYy6kNf0DahdTdR8PBAa4vVTP9jD74XKT72aUSqinsDymwAdel4Ae4Ulkutf77CnEbiwdI7cgikYnaACGnDbBpmcB5RARETts2OhHB2LHg3SUGH_2NYe2NN_PV7UL37g

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #329

                                        but than it wouldn't really make sense to take over from Pfizer ? they could have joined them
                                        ?

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #330

                                          You know with JNJ or Abbvie to make one BP 😉

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper